NDAORALCAPSULE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMCYT is an oral estramustine phosphate sodium capsule, a conjugate of estradiol and mechlorethamine, indicated for prostate cancer. It combines hormonal and alkylating chemotherapy mechanisms to target hormone-responsive malignancies.
$0.043BPart D
LOE ApproachingDeclining
Very small, legacy franchise with minimal active commercial investment; roles are likely support-focused rather than growth-oriented.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EMCYT offers very limited career growth opportunities due to its legacy status, minimal claims volume (44 in 2023), and approaching loss of exclusivity. Roles are primarily support-focused on maintaining existing patient relationships rather than driving innovation or expansion.
Product ManagerMarket Access Manager
Worked on EMCYT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.